Oncotarget , 7, 58405 58417
LARS, as a GTPase-activating protein (GAP), interacts with Rag GTPase (Han et al., 2012) or directly mediates leucylation of RagA/B (He et al., 2018), to activate mTORC1
Collagen peptides accelerate skin structure rebuilding, smoothing fine lines and lifting sagging areas to create a tighter, more youthful appearance
Metabotropic glutamate receptors and neuroadaptation to antidepressants: Imipramine-induced down-regulation of -adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands
Dose adjustment strategies: If symptoms are intolerable despite supportive measures, your prescriber may recommend: Slowing the titration schedule (extending time at each dose level) Temporarily reducing to the previous tolerated dose Maintaining the once-weekly injection schedule (timing within the day has limited evidence for efficacy) When to seek medical review: Symptoms persisting beyond 46 weeks at stable dose Inability to maintain adequate nutrition or hydration Weight loss exceeding expected therapeutic effect New or severe abdominal pain Signs of pancreatitis (severe upper abdominal pain radiating to back) Symptoms of gallbladder disease (right upper quadrant pain, jaundice) Patient safety advice : Discuss any dose changes or stopping with your prescriber
